Antibody Il2 Fusion Protein Delivery By Gene Transfer
Download Antibody Il2 Fusion Protein Delivery By Gene Transfer full books in PDF, epub, and Kindle. Read online free Antibody Il2 Fusion Protein Delivery By Gene Transfer ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
| Author | : |
| Publisher | : |
| Total Pages | : 0 |
| Release | : 1997 |
| Genre | : |
| ISBN | : |
Our team has pursued preclinical and clinical investigations combining the administration of IL-2 with tumor reactive monoclonal antibodies. Preclinical models, developed by our collaborators R. Reisfeld and S. Gillies, have shown the antitumor efficacy of antibody-IL2 fusion proteins in murine models. The KS-IL2 fusion protein recognizes the KSA antigen expressed on a broad range of human carcinomas, including breast cancer and is effective at preventing outgrowth of the KSA positive, syngeneic CT26-KSA carcinoma cell line in mice. The experiments now underway in this research study are designed to help improve the future clinical efficacy of the KS-IL2 reagent by clarifying its actions, testing its efficacy in murine models simulating pitfalls with human immunotherapy, and translating these results to human application through in vitro studies.
| Author | : Stefan R. Schmidt |
| Publisher | : John Wiley & Sons |
| Total Pages | : 995 |
| Release | : 2013-01-28 |
| Genre | : Medical |
| ISBN | : 1118354583 |
The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs—with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protein was launched. Fusion Protein Technologies for Biopharmaceuticals examines the state of the art in developing fusion proteins for biopharmaceuticals, shedding light on the immense potential inherent in fusion protein design and functionality. A wide pantheon of international scientists and researchers deliver a comprehensive and complete overview of therapeutic fusion proteins, combining the success stories of marketed drugs with the dynamic preclinical and clinical research into novel drugs designed for as yet unmet medical needs. The book covers the major types of fusion proteins—receptor-traps, immunotoxins, Fc-fusions and peptibodies—while also detailing the approaches for developing, delivering, and improving the stability of fusion proteins. The main body of the book contains three large sections that address issues key to this specialty: strategies for extending the plasma half life, the design of toxic proteins, and utilizing fusion proteins for ultra specific targeting. The book concludes with novel concepts in this field, including examples of highly relevant multifunctional antibodies. Detailing the innovative science, commercial realities, and brilliant potential of fusion protein therapeutics, Fusion Protein Technologies for Biopharmaceuticals is a must for pharmaceutical scientists, biochemists, medicinal chemists, molecular biologists, pharmacologists, and genetic engineers interested in determining the shape of innovation in the world of biopharmaceuticals.
| Author | : Steven M. Chamow |
| Publisher | : Wiley-Liss |
| Total Pages | : 312 |
| Release | : 1999-04-13 |
| Genre | : Science |
| ISBN | : 9780471183587 |
Thoroughly detailed and illustrated, this book examines the construction, properties, applications, and problems associated with specific types of fusion molecules used in clinical and research medicine. The editors present an overview of the field, followed by nine chapters divided into two general sections based on the two primary parts of the antibody molecule: Fab fusion proteins and Fc fusion proteins. In addition, numerous renowned scientists in the field have contributed outlines demonstrating man-made molecules that will be required not only to overcome the limitations of monoclonal antibodies, but also to extend the principle of selective targeting. Divided into specific, accessible sections, Antibody Fusion Proteins includes: * Chapters describing Fc fusion proteins, as well as several classes of antigen-binding proteins * Complete details on the design and molecular construction of genetically engineered fusion molecules * Useful information on molecular purification, large-scale production, practical applications, and their therapeutic potential * The latest data on forming fusion proteins with toxins, cytokines, or enzymes that can activate a prodrug
| Author | : S Prakash |
| Publisher | : Elsevier |
| Total Pages | : 537 |
| Release | : 2007-05-31 |
| Genre | : Science |
| ISBN | : 1845693078 |
Artificial cells, cell engineering and therapy are emerging technologies which will make a significant impact on the future of medicine and healthcare. However, research within the field is vast. This unique book provides a comprehensive study of the most recent advances in the field and its practical applications. The first part of the book offers the reader an introduction to the basics of artificial cell technology with chapters on its origins, design, current status within medicine and future prospects. Part two covers apoptosis, the use of bone marrow stromal cells in myocardial regeneration together with signalling and tissue engineering. Part three discusses artificial cells for therapy, procedures for various clinical conditions and the current status of the discipline within the field. The book concludes with a final section on the role of artificial cells in medicine with particular focus on the use of artificial cells as blood substitutes and their potential use in myocardial regeneration, drug delivery and in treating kidney and bowel diseases, diabetes and cancer. Artificial cells, cell engineering and therapy is a valuable reference for researchers, students and practitioners within the field. Introduces the basics of artificial cell technology Provides a comprehensive study of the most recent advances in artificial cells, cell engineering and cell therapy Discusses the design, engineering and uses of artificial cells
| Author | : National Cancer Institute (U.S.). Division of Cancer Biology, Diagnosis, and Centers |
| Publisher | : |
| Total Pages | : 746 |
| Release | : 1995 |
| Genre | : |
| ISBN | : |
| Author | : Kelly K. Hunt |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 469 |
| Release | : 2007-10-26 |
| Genre | : Medical |
| ISBN | : 159745222X |
The three sections of this volume present currently available cancer gene therapy techniques. Part I describes the various aspects of gene delivery. In Part II, the contributors discuss strategies and targets for the treatment of cancer. Finally, in Part III, experts discuss the difficulties inherent in bringing gene therapy treatment for cancer to the clinic. This book will prove valuable as the volume of preclinical and clinical data continues to increase.
| Author | : Gerald J. Prud'homme |
| Publisher | : Springer |
| Total Pages | : 149 |
| Release | : 2005-07-13 |
| Genre | : Medical |
| ISBN | : 9780306479915 |
Autoimmune diseases are diverse and responsible for considerable morbidity. Their etiology remains largely unknown, and current therapy with anti-inflammatory drugs is prone to adverse effects, and rarely curative. New therapies with anti-cytokine antibodies or receptors are promising, but require frequent administration of expensive protein drugs. Gene Therapy of Autoimmune Diseases comprehensively reviews research in gene therapy for autoimmune diseases with viral or non-viral vectors. Gene therapy offers the possibility of long-term, continuous delivery of a wide variety of immunosuppressive, anti-inflammatory, or tolerance-inducing agents. Moreover, highly specific genetically modified cells can be produced. This book discusses the most promising avenues in this exciting new field.
| Author | : You Han Bae |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 717 |
| Release | : 2013-08-31 |
| Genre | : Medical |
| ISBN | : 1461478766 |
This book was conceived from a simple question as to why cancer is so difficult to treat. Ultimately we want to find ways to cure cancers, but that may be an elusive dream at least with the technologies we have now and expect to have in the near future. This leads the question of whether it is possible to improve current cancer treatment methods, especially from the perspective of enhancing targeted drug delivery to tumors. This volume is designed to provide information related to the difficulties in treating cancers through targeted drug delivery, our current understanding of cancer biology, and potential technologies that might be used to achieve enhanced drug delivery to tumors. An ideal drug delivery system for treating cancers would maximize the therapeutic efficacy with minimal side effects in clinical applications. The seemingly improved anticancer efficacy of the current nanoparticle-based formulations needs to be viewed from the context of very poor success rates for translation to human applications. The results of in vitro cell culture models and small animal in vivo experiments have not been extrapolated to clinical applications. Finding the reasons for the lack of successful translation is required if we are to discover approaches to substantially extend the survival time of cancer patients, and hopefully identify cures. Cancer Targeted Drug Delivery: Elusive Dream describes some answers of achieving the so far elusive dream of treating cancers like other chronic diseases with therapies that focus using improved drug delivery systems designed to better align with the unique biological and physiological properties of cancer.
| Author | : Leonidas C. Platanias |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 381 |
| Release | : 2006-05-06 |
| Genre | : Medical |
| ISBN | : 0387243615 |
The first book to cover both basic science and clinical research, providing a comprehensive review of the current knowledge on cytokines and cancer. Written by leading figures in the field of cytokine biology and cytokine therapeutics.
| Author | : R. John Bicknell |
| Publisher | : |
| Total Pages | : 416 |
| Release | : 1997 |
| Genre | : Neovascularization |
| ISBN | : |
Tumour Angiogenesis is the first comprehensive book to cover all areas of this rapidly expanding research area. Each chapter is written by world experts in the field and topics covered include in vivo models, mechanisms, inhibition, and the role of macrophages, cytokines, proteases,extracellular matrix components, nitric oxide, prostanoids and oncogenes/tumour suppressor genes in angiogenesis. Other chapters examine the role of specific growth factors in angiogenesis - these include vascular endothelial growth factor, the basic fibroblast growth factor family, transforminggrowth factor-beta, tumour necrosis factor-alpha, platelet-derived endothelial cell growth factor/thymidine phosphorylase and pleiotrophin and related molecules. Clinical issues are addressed in chapters that deal with the prognostic and predictive value of tumour microvessel density and thetherapeutic significance of microregional blood flow. The two final chapters examine the feasibility of targeting tumour vasculature using either antibodies or gene therapy.
